Table 5

Primary outcome and subgroup analyses of the chronic obstructive pulmonary disease (COPD) patients’ health characteristics: adjusted mean differences in physical component summary (PCS) and mental component summary (MCS) scores for the total sample and subgroups, adjusted for respective baseline PCS or baseline MCS and age, gender, baseline forced expiratory volume in one second of predicted normal (FEV1), marital status, cancer and diabetes

Health characteristics
Effectiveness
Total sample
PCS
0.1
PCS 95% CI
(−1.4 to 1.7)
Wald test
p value
ICC
0.0
MCS
0.4
MCS 95% CI
(−1.7 to 2.4)
Wald test
p value
ICC
0.0
COPD severity (GOLD 1–4)
 Mild, 1 (6%)1.7(−4.7 to 8.2)0.70.00.6(−6.8 to 8.1)0.80.0
 Moderate, 2 (38%)−0.7(−3.0 to 1.5)−0.7(−3.8 to 2.4)
 Severe, 3 (39%)1.0(−1.7 to 3.7)1.5(−2.1 to 5.1)
 Very severe, 4 (17%)−0.6(−4.8 to 3.5)−0.2(−5.2 to 4.8)
COPD duration (years)
 <3.5 (25%)−0.7(−2.9 to 1.6)0.30.0−1.0(−4.4 to 2.4)0.10.0
 3.5–6 (26%)−1.6(−4.6 to 1.4)−2.0(−5.7 to 1.6)
 7–10 (26%)0.5(−2.8 to 3.8)0.5(−3.6 to 4.7)
 >10 (23%)2.5(−0.7 to 5.7)4.0(−0.2 to 8.2)
Diabetes
 No (89%)0.3(−1.2 to 1.9)0.40.00.3(−1.8 to 2.5)0.90.0
 Yes (11%)−1.4(−5.3 to 2.4)0.7(−4.9 to 6.4)
Heart disease
 No (65%)0.1(−1.5 to 1.6)0.90.00.7(−1.7 to 3.2)0.60.0
 Yes (35%)0.3(−2.6 to 3.2)−0.3(−3.7 to 3.1)
Mental health problem
 No (95%)0.3(−1.3 to 1.9)0.30.00.3(−1.8 to 2.4)0.80.0
 Yes (5%)−3.1(−8.7 to 2.5)1.5(−6.2 to 9.2)
Musculoskeletal disease
 No (70%)0.1(−1.7 to 1.8)0.90.00.5(−1.6 to 2.6)0.70.0
 Yes (30%)0.2(−2.0 to 2.5)−0.1(−3.5 to 3.3)
Cancer
 No (94%)0.0(−1.4 to 1.5)0.50.00.2(−1.85 to 2.28)0.60.0
 Yes (6%)2.1(−4.7 to 8.9)2.7(−5.4 to 10.7)
Number of comorbidities
 Yes (33%)0.3(−2.1 to 2.6)0.10.00.3(−2.8 to 3.4)0.70.0
 No (41%)1.4(−1.0 to 3.8)1.0(−2.2 to 4.2)
 Two or more (26%)−2.0(−4.9 to 1.0)−0.7(−4.3 to 2.9)
Hypertension
 Yes (71%)0.6(−1.3 to 2.5)0.30.00.4(−2.1 to 2.9)1.00.0
 No (29%)−1.1(−3.7 to 1.4)0.3(−3.3 to 3.9)
Tachycardia
 Yes (70%)0.3(−1.4 to 1.9)0.80.00.1(−2.0 to 2.2)0.70.0
 No (30%)−0.2(−3.3 to 3.0)1.0(−2.8 to 4.9)
BMI
 <25 (44%)0.4(−2.1 to 2.8)1.00.00.5(−2.9 to 3.7)1.00.0
 25–30 (34%)0.2(−2.5 to 2.9)−0.1(−3.8 to 3.6)
 >30 (22%)−0.4(−4.5 to 3.6)0.8(−4.0 to 5.6)
  • All data are based on norms-based scoring.

  • Multilevel linear models controlling for baseline PCS or MCS score and age, gender, baseline FEV1, marital status, cancer and diabetes and clustering. Priori hypothesis was that adding telehealthcare to usual practice would improve patients’ health-related quality of life relative to usual practice.

  • Mean difference; 95% CIs.

  • GOLD, Global Initiative for COPD; ICC, intraclass coefficient.